ClinicalTrials.Veeva

Menu

The Use of Indocyanine Green to Visualize Blood Flow to the Gastrojejunostomy During Bariatric Surgery.

University Health Network, Toronto logo

University Health Network, Toronto

Status and phase

Enrolling
Phase 4

Conditions

Ulcer, Gastric
Obesity, Morbid

Treatments

Device: Stryker 1688 AIM system
Drug: Indocyanine green

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT06002906
20-5008

Details and patient eligibility

About

This is an interventional pilot study aimed to evaluate the use of NIF imaging as an intraoperative aid to assess the anastomotic blood flow to the gastric pouch and gastrojejunostomy during Roux-en-Y gastric bypass surgery and to determine its long-term impact on the rate of marginal ulceration, leaks and stricture.

Full description

The purpose of this study is to examine intraoperative usefulness of near-infrared light fluorescence imaging with a contrast agent called indocyanine green to improve visualization of blood flow to a surgical connection between the small intestine and stomach (gastrojejunostomy) in patients undergoing gastric bypass surgery. ICG will be given prior to and after making the gastrojejunostomy to examine blood flow and then a subjective perfusion score will be given by the surgeon and assistant during the surgery.

Patients will be recruited before the laparoscopic Roux-en-Y gastric bypass surgery and the study data will be collected prospectively through standard bariatric follow up visits up to 2 years. A mid-term analysis of the procedure and patient outcomes will be performed for quality assurance purposes when half the study patients have undergone intraoperative ICG use. The ICG will be not given if a patient is allergic to sodium iodide or has a history of allergy to iodides because of the risk of a severe allergic reaction.

Participants will be assigned an identifying number to protect confidentiality. Descriptive univariate and multivariate statistical analysis will be performed on all patients satisfying the study's inclusion criteria.

Enrollment

300 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Capacity to provide informed consent.
  • Over the Age of 18.
  • Eligible for bariatric surgery in Ontario and deemed an appropriate candidate for RYGB surgery by the bariatric program.
  • Commit to follow-up within the bariatric program, including behavioral and dietary modifications designed to aid in sustained weight-loss.
  • Treatment of marginal ulcer with the revisional surgery.

Exclusion criteria

  • Not willing to participate in study
  • Contraindication to, or not planned to undergo RYGB
  • Known allergy to indocyanine green or Sodium Iodide
  • Is participant pregnant or planning to get pregnant in next two years
  • Ongoing substance abuse or active smoking
  • Bleeding diathesis or Coagulopathy
  • Unwilling to take PPI medication Post operatively

Trial design

Primary purpose

Prevention

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

300 participants in 1 patient group

Interventional group (with drug)
Experimental group
Description:
The interventional group will receive indocyanine green during bariatric surgery inside the operating room before and after making the gastrojejunostomy.
Treatment:
Drug: Indocyanine green
Device: Stryker 1688 AIM system

Trial contacts and locations

1

Loading...

Central trial contact

Priya Sharma; Allan Okrainec, MDCM, MHPE

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems